Nuvalent (NUVL) Change in Accured Expenses (2020 - 2026)
Nuvalent (NUVL) posted Change in Accured Expenses of -$2.1 million for Q1 2026, up 65.79% on a QoQ basis from -$6.2 million in Q4 2025, and down 471.85% year-over-year from $573618.6 in Q1 2025.
Nuvalent (NUVL) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Nuvalent's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$2.1 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 471.85% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 66.02% YoY) and the FY2025 annual result came in at $11.5 million, down 57.34% from the prior year.
- Change in Accured Expenses was -$2.1 million for Q1 2026 at Nuvalent, up from -$6.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $13.7 million in Q4 2024 and bottomed at -$6.2 million in Q4 2025.
- A 5-year average of $3.0 million and a median of $2.5 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 5382.35% — and 2026, when it tumbled 471.85%.
- Nuvalent's Change in Accured Expenses stood at $4.5 million in 2022, then dropped by 14.03% to $3.8 million in 2023, then jumped by 257.18% to $13.7 million in 2024, then sank by 145.35% to -$6.2 million in 2025, then soared by 65.79% to -$2.1 million in 2026.
- Business Quant data shows NUVL's Change in Accured Expenses at -$2.1 million in Q1 2026, -$6.2 million in Q4 2025, and $5.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.13 Mn |
| Mar 31, 2026 | -2.13 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | 12.84 Mn |
| Jun 30, 2025 | 12.84 Mn |
| Mar 31, 2025 | -373,000.00 |
| Mar 31, 2025 | -373,000.00 |
| Dec 31, 2024 | 13.75 Mn |
| Dec 31, 2024 | 13.75 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 10.91 Mn |
| Jun 30, 2024 | 10.91 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Dec 31, 2023 | 3.85 Mn |